Call for Papers  

Article Details


PDE10A Inhibitors: Novel Therapeutic Drugs for Schizophrenia

[ Vol. 17 , Issue. 2 ]

Author(s):

Jan Kehler and Jacob Nielsen   Pages 137 - 150 ( 14 )

Abstract:


Disturbances of the basal ganglia processes is heavily involved in schizophrenia. Phosphodiesterase 10A (PDE10A) is a basal ganglia specific hydrolase, which plays an essential role in regulating cAMP/PKA and cGMP/PKG signalling cascades by controlling the magnitude, duration and cellular location of cAMP/cGMP elevation. Biochemical and behavioral data indicate that PDE10A inhibition activates cAMP/PKA signalling in the basal ganglia, leading to the potentiation of dopamine D1 receptor signalling, and concomitant inhibition of dopamine D2 receptor signalling. Preclinical evidence in a range of animal models suggests that a PDE10A inhibitor could provide efficacy on positive, cognitive and negative symptoms of schizophrenia and PDE10A inhibitors are currently being evaluated in clinical trials for the treatment of schizophrenia.

Keywords:

Basal ganglia,Phosphodiesterase 10A,PDE10A,schizophrenia,psychosis,antipsychotic,cAMP/PKG,cGMP/PKG,signalling cascades,dopamine,pro-cognitive,striatopallidal,striatonigral,PDE10A structure

Affiliation:

, Ottiliavej 9, DK-2500 valby,Denmark/ H. Lundbeck A/S dept. Medicinal chemistry.



Read Full-Text article